Vanguard Group Inc. Buys 305020 Shares of Cara Therapeutics Inc (CARA)

Vanguard Group Inc. increased its position in Cara Therapeutics Inc (NASDAQ:CARA) by 24.5% during the third quarter, according to its most recent …

Cara Therapeutics logoVanguard Group Inc. increased its position in Cara Therapeutics Inc (NASDAQ:CARA) by 24.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,551,344 shares of the biopharmaceutical company’s stock after buying an additional 305,020 shares during the period. Vanguard Group Inc. owned 3.95% of Cara Therapeutics worth $37,155,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in CARA. Pacer Advisors Inc. acquired a new position in Cara Therapeutics during the third quarter worth $138,000. Creative Planning acquired a new position in Cara Therapeutics during the third quarter worth $207,000. HAP Trading LLC raised its stake in Cara Therapeutics by 207.5% during the third quarter. HAP Trading LLC now owns 10,753 shares of the biopharmaceutical company’s stock worth $258,000 after acquiring an additional 20,753 shares in the last quarter. Virtu Financial LLC acquired a new position in Cara Therapeutics during the third quarter worth $259,000. Finally, Raymond James & Associates acquired a new position in Cara Therapeutics during the second quarter worth $250,000. 62.16% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:CARA traded up $0.08 during trading on Tuesday, hitting $17.13. 169,855 shares of the company’s stock traded hands, compared to its average volume of 624,717. Cara Therapeutics Inc has a 52 week low of $11.46 and a 52 week high of $24.30. The stock has a market capitalization of $669.89 million, a PE ratio of -9.21 and a beta of 2.87.

Several research analysts have issued reports on the company. Janney Montgomery Scott assumed coverage on Cara Therapeutics in a research note on Thursday, December 20th. They set a “buy” rating and a $13.36 price objective for the company. Zacks Investment Research lowered Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, January 21st. HC Wainwright set a $30.00 target price on Cara Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 20th. Bank of America assumed coverage on Cara Therapeutics in a research note on Tuesday, January 15th. They issued a “neutral” rating and a $19.00 target price for the company. Finally, BidaskClub lowered Cara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $24.03.

In other Cara Therapeutics news, CEO Derek T. Chalmers sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $14.99, for a total transaction of $299,800.00. Following the transaction, the chief executive officer now owns 953,788 shares of the company’s stock, valued at approximately $14,297,282.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mani Mohindru sold 4,500 shares of the business’s stock in a transaction that occurred on Friday, December 28th. The stock was sold at an average price of $12.55, for a total value of $56,475.00. The disclosure for this sale can be found here. In the last three months, insiders sold 95,450 shares of company stock worth $1,266,845. 6.70% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Vanguard Group Inc. Buys 305,020 Shares of Cara Therapeutics Inc (CARA)” was first reported by Fairfield Current and is owned by of Fairfield Current. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.fairfieldcurrent.com/news/2019/02/19/vanguard-group-inc-increases-stake-in-cara-therapeutics-inc-cara.html.

Cara Therapeutics Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.

Featured Story: Day Trading

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cara Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Vanguard Group Inc. Increases Stake in Cara Therapeutics Inc (CARA)

Vanguard Group Inc. lifted its holdings in Cara Therapeutics Inc (NASDAQ:CARA) by 24.5% in the 3rd quarter, according to its most recent filing with …

Cara Therapeutics logoVanguard Group Inc. lifted its holdings in Cara Therapeutics Inc (NASDAQ:CARA) by 24.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,551,344 shares of the biopharmaceutical company’s stock after purchasing an additional 305,020 shares during the period. Vanguard Group Inc. owned about 3.95% of Cara Therapeutics worth $37,155,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in CARA. Morgan Stanley lifted its holdings in Cara Therapeutics by 6.3% during the third quarter. Morgan Stanley now owns 81,338 shares of the biopharmaceutical company’s stock valued at $1,948,000 after purchasing an additional 4,840 shares in the last quarter. B. Riley Wealth Management Inc. purchased a new position in Cara Therapeutics during the third quarter valued at $882,000. TIAA CREF Investment Management LLC lifted its holdings in Cara Therapeutics by 19.2% during the third quarter. TIAA CREF Investment Management LLC now owns 70,240 shares of the biopharmaceutical company’s stock valued at $1,682,000 after purchasing an additional 11,312 shares in the last quarter. Teachers Advisors LLC lifted its holdings in Cara Therapeutics by 15.4% during the third quarter. Teachers Advisors LLC now owns 63,265 shares of the biopharmaceutical company’s stock valued at $1,515,000 after purchasing an additional 8,461 shares in the last quarter. Finally, Nexthera Capital LP lifted its holdings in Cara Therapeutics by 69.2% during the third quarter. Nexthera Capital LP now owns 737,303 shares of the biopharmaceutical company’s stock valued at $17,658,000 after purchasing an additional 301,503 shares in the last quarter. 62.16% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:CARA traded up $0.01 during midday trading on Tuesday, hitting $16.38. The company’s stock had a trading volume of 3,837 shares, compared to its average volume of 639,580. The company has a market cap of $660.08 million, a P/E ratio of -8.94 and a beta of 2.87. Cara Therapeutics Inc has a 12-month low of $11.46 and a 12-month high of $24.30.

Several equities analysts have issued reports on the stock. Cantor Fitzgerald set a $27.00 price objective on shares of Cara Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 7th. Zacks Investment Research downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 9th. BidaskClub downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 1st. Jefferies Financial Group assumed coverage on shares of Cara Therapeutics in a report on Wednesday, February 6th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, Bank of America assumed coverage on shares of Cara Therapeutics in a report on Tuesday, January 15th. They set a “neutral” rating and a $19.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $24.03.

In other news, CEO Derek T. Chalmers sold 20,000 shares of the firm’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $14.99, for a total value of $299,800.00. Following the transaction, the chief executive officer now directly owns 953,788 shares of the company’s stock, valued at $14,297,282.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Scott Terrillion sold 3,100 shares of the firm’s stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $12.51, for a total transaction of $38,781.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 111,492 shares of company stock worth $1,563,622. Insiders own 6.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Fairfield Current and is the property of of Fairfield Current. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.fairfieldcurrent.com/news/2019/02/12/vanguard-group-inc-increases-stake-in-cara-therapeutics-inc-cara.html.

About Cara Therapeutics

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.

Featured Story: What is Depreciation?

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cara Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Horrell Capital Management, Inc. Buys NetScout Systems Inc, MicroStrategy Inc, Juniper Networks …

Little Rock, AR, based Investment company Horrell Capital Management, Inc. buys NetScout Systems Inc, MicroStrategy Inc, Juniper Networks Inc, iKang Healthcare Group Inc, Nokia Oyj, Ribbon Communications Inc, iShares U.S. Preferred Stock ETF, Cara Therapeutics Inc, JD.com Inc, iShares Russell …

Little Rock, AR, based Investment company Horrell Capital Management, Inc. buys NetScout Systems Inc, MicroStrategy Inc, Juniper Networks Inc, iKang Healthcare Group Inc, Nokia Oyj, Ribbon Communications Inc, iShares U.S. Preferred Stock ETF, Cara Therapeutics Inc, JD.com Inc, iShares Russell 2000, sells Team Inc, LM Ericsson Telephone Co, Deltic Timber Corp, Heidrick & Struggles International Inc, Syntel Inc during the 3-months ended 2018-03-31, according to the most recent filings of the investment company, Horrell Capital Management, Inc.. As of 2018-03-31, Horrell Capital Management, Inc. owns 159 stocks with a total value of $184 million. These are the details of the buys and sells.

For the details of Horrell Capital Management, Inc.’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Horrell+Capital+Management%2C+Inc.

These are the top 5 holdings of Horrell Capital Management, Inc.

  1. Union Pacific Corp (UNP) – 84,736 shares, 6.21% of the total portfolio. Shares added by 2.67%
  2. Dassault Systemes SE (DASTY) – 58,810 shares, 4.35% of the total portfolio. Shares added by 2.67%
  3. FedEx Corp (FDX) – 29,423 shares, 3.85% of the total portfolio. Shares added by 2.67%
  4. Bear State Financial Inc (BSF) – 668,868 shares, 3.74% of the total portfolio. Shares reduced by 21.85%
  5. Convergys Corp (CVG) – 300,000 shares, 3.7% of the total portfolio.

New Purchase: NetScout Systems Inc (NTCT)

Horrell Capital Management, Inc. initiated holding in NetScout Systems Inc. The purchase prices were between $25.5 and $31.35, with an estimated average price of $27.19. The stock is now traded at around $27.35. The impact to a portfolio due to this purchase was 2.43%. The holding were 169,000 shares as of 2018-03-31.

New Purchase: MicroStrategy Inc (MSTR)

Horrell Capital Management, Inc. initiated holding in MicroStrategy Inc. The purchase prices were between $123.87 and $140.98, with an estimated average price of $134.57. The stock is now traded at around $128.73. The impact to a portfolio due to this purchase was 2.39%. The holding were 34,009 shares as of 2018-03-31.

New Purchase: iKang Healthcare Group Inc (KANG)

Horrell Capital Management, Inc. initiated holding in iKang Healthcare Group Inc. The purchase prices were between $15.64 and $20, with an estimated average price of $16.81. The stock is now traded at around $20.03. The impact to a portfolio due to this purchase was 0.87%. The holding were 80,000 shares as of 2018-03-31.

New Purchase: iShares U.S. Preferred Stock ETF (PFF)

Horrell Capital Management, Inc. initiated holding in iShares U.S. Preferred Stock ETF. The purchase prices were between $36.79 and $38.19, with an estimated average price of $37.53. The stock is now traded at around $37.31. The impact to a portfolio due to this purchase was 0.01%. The holding were 500 shares as of 2018-03-31.

New Purchase: iShares Russell 2000 (IWM)

Horrell Capital Management, Inc. initiated holding in iShares Russell 2000. The purchase prices were between $145.44 and $159.96, with an estimated average price of $154.44. The stock is now traded at around $153.91. The impact to a portfolio due to this purchase was less than 0.01%. The holding were 50 shares as of 2018-03-31.

New Purchase: Shopify Inc (SHOP)

Horrell Capital Management, Inc. initiated holding in Shopify Inc. The purchase prices were between $105.49 and $153.11, with an estimated average price of $129.43. The stock is now traded at around $122.05. The impact to a portfolio due to this purchase was less than 0.01%. The holding were 50 shares as of 2018-03-31.

Added: Juniper Networks Inc (JNPR)

Horrell Capital Management, Inc. added to a holding in Juniper Networks Inc by 63.64%. The purchase prices were between $24.05 and $28.89, with an estimated average price of $26.58. The stock is now traded at around $24.78. The impact to a portfolio due to this purchase was 0.93%. The holding were 180,000 shares as of 2018-03-31.

Added: Nokia Oyj (NOK)

Horrell Capital Management, Inc. added to a holding in Nokia Oyj by 55.56%. The purchase prices were between $4.76 and $5.93, with an estimated average price of $5.39. The stock is now traded at around $5.61. The impact to a portfolio due to this purchase was 0.75%. The holding were 700,000 shares as of 2018-03-31.

Added: Ribbon Communications Inc (RBBN)

Horrell Capital Management, Inc. added to a holding in Ribbon Communications Inc by 61.75%. The purchase prices were between $5.08 and $7.83, with an estimated average price of $6.47. The stock is now traded at around $5.30. The impact to a portfolio due to this purchase was 0.54%. The holding were 510,800 shares as of 2018-03-31.

Added: GW Pharmaceuticals PLC (GWPH)

Horrell Capital Management, Inc. added to a holding in GW Pharmaceuticals PLC by 66.67%. The purchase prices were between $110.14 and $139.71, with an estimated average price of $125.74. The stock is now traded at around $118.95. The impact to a portfolio due to this purchase was less than 0.01%. The holding were 100 shares as of 2018-03-31.

Added: Cara Therapeutics Inc (CARA)

Horrell Capital Management, Inc. added to a holding in Cara Therapeutics Inc by 100.00%. The purchase prices were between $11.77 and $16.08, with an estimated average price of $13.47. The stock is now traded at around $12.41. The impact to a portfolio due to this purchase was less than 0.01%. The holding were 400 shares as of 2018-03-31.

Sold Out: Team Inc (TISI)

Horrell Capital Management, Inc. sold out a holding in Team Inc. The sale prices were between $13.2 and $18.75, with an estimated average price of $16.46.

Sold Out: LM Ericsson Telephone Co (ERIC)

Horrell Capital Management, Inc. sold out a holding in LM Ericsson Telephone Co. The sale prices were between $6.2 and $7.34, with an estimated average price of $6.73.

Sold Out: Deltic Timber Corp (DEL)

Horrell Capital Management, Inc. sold out a holding in Deltic Timber Corp. The sale prices were between $88.07 and $100.17, with an estimated average price of $93.41.

Sold Out: Heidrick & Struggles International Inc (HSII)

Horrell Capital Management, Inc. sold out a holding in Heidrick & Struggles International Inc. The sale prices were between $24.1 and $32.45, with an estimated average price of $27.31.

Sold Out: YuMe Inc (YUME)

Horrell Capital Management, Inc. sold out a holding in YuMe Inc. The sale prices were between $3.66 and $4.8, with an estimated average price of $4.36.

Sold Out: Cray Inc (CRAY)

Horrell Capital Management, Inc. sold out a holding in Cray Inc. The sale prices were between $20.05 and $25.85, with an estimated average price of $23.18.

Reduced: Syntel Inc (SYNT)

Horrell Capital Management, Inc. reduced to a holding in Syntel Inc by 95%. The sale prices were between $21.2 and $27.44, with an estimated average price of $24.78. The stock is now traded at around $25.25. The impact to a portfolio due to this sale was -1.16%. Horrell Capital Management, Inc. still held 5,000 shares as of 2018-03-31.

Reduced: Bear State Financial Inc (BSF)

Horrell Capital Management, Inc. reduced to a holding in Bear State Financial Inc by 21.85%. The sale prices were between $10.22 and $10.32, with an estimated average price of $10.27. The stock is now traded at around $10.30. The impact to a portfolio due to this sale was -1.02%. Horrell Capital Management, Inc. still held 668,868 shares as of 2018-03-31.

Reduced: Marchex Inc (MCHX)

Horrell Capital Management, Inc. reduced to a holding in Marchex Inc by 58.56%. The sale prices were between $2.64 and $3.55, with an estimated average price of $3.23. The stock is now traded at around $2.67. The impact to a portfolio due to this sale was -0.4%. Horrell Capital Management, Inc. still held 166,117 shares as of 2018-03-31.

Reduced: Allot Communications Ltd (ALLT)

Horrell Capital Management, Inc. reduced to a holding in Allot Communications Ltd by 57.73%. The sale prices were between $4.85 and $5.74, with an estimated average price of $5.33. The stock is now traded at around $5.44. The impact to a portfolio due to this sale was -0.36%. Horrell Capital Management, Inc. still held 94,300 shares as of 2018-03-31.

Reduced: Campbell Soup Co (CPB)

Horrell Capital Management, Inc. reduced to a holding in Campbell Soup Co by 33.33%. The sale prices were between $42.02 and $48.11, with an estimated average price of $45.12. The stock is now traded at around $43.06. The impact to a portfolio due to this sale was -0.01%. Horrell Capital Management, Inc. still held 500 shares as of 2018-03-31.

Here is the complete portfolio of Horrell Capital Management, Inc.. Also check out:

1. Horrell Capital Management, Inc.’s Undervalued Stocks

2. Horrell Capital Management, Inc.’s Top Growth Companies, and

3. Horrell Capital Management, Inc.’s High Yield stocks

4. Stocks that Horrell Capital Management, Inc. keeps buying

Related Posts:

Have Experts Now Turned Bearish On Cara Therapeutics, Inc. (CARA), QUALCOMM Incorporated …

Cara Therapeutics, Inc. (NASDAQ:CARA) recently ticked higher on weak volume. About 1.04 million contracts were traded on 21-Mar-18 compared to daily average volume of 1.06 million shares. The first sale was made at $11.79 but later the stock became weaker, and closed with a gain of 4.67%.

Cara Therapeutics, Inc. (NASDAQ:CARA) recently ticked higher on weak volume. About 1.04 million contracts were traded on 21-Mar-18 compared to daily average volume of 1.06 million shares. The first sale was made at $11.79 but later the stock became weaker, and closed with a gain of 4.67%. It was last traded at $12.32 apiece.

Cara Therapeutics, Inc. (CARA): Outperform Candidate With 104.3% Upside Potential

Cara Therapeutics, Inc. is maintained at an average outperform rating by 7 stock analysts, and there are at least 21.66% of shares outstanding that are currently legally short sold. The shares went down by -10.79% in value last month. Year-to-date it jumped 0.65%. Analysts are turning out to be more optimistic than before, with 7 of analysts who cover Cara Therapeutics, Inc. (NASDAQ:CARA) advice adding it to buy candidate list. Wall Street experts also assign a $25.17 price target on Cara Therapeutics, Inc., pointing towards a 104.3% rally from current levels. The stock is trading for about -56.77% less than its 52-week high.

CARA Retreats -10.98% In A Week

This company shares (CARA) so far managed to recover 10.89% since collapsing to its 52-week low. Over a month, it has seen its stock price volatility to stay at 8.06% while shortening the period to a week, volatility was 5.13%. The share price has yet to cross its 20 days moving average, floating at a distance of -10.78% and sits -9.9% lower versus its 50 days moving average. When looking at the past five sessions, the stock returned -10.98% losses and is down by -12.03% compared with its 200-day moving average of $13.16. Also, Cara Therapeutics, Inc. (CARA) needs to overturn a -20.92% decrease it experienced over the past twelve months.

QUALCOMM Incorporated (NASDAQ:QCOM) Consensus Call At 2.3

As regular trading ended, QUALCOMM Incorporated (QCOM) stock brought in a -$1.45 drop to $56.81. The day started at a price of $57.5 but then traded as high as $58.28 before giving part of the gains back. As for this week, analysts appear content to stick with their neutral outlook with the consensus call at 2.3. QUALCOMM Incorporated is given 5 buy-equivalent recommendations, 0 sells and 13 holds. The company shares sank -18% from their peak of $69.28 and now has a $83.09 billion market value of equity.

QUALCOMM Incorporated Could Grow 25.03% More

QCOM’s mean recommendation on Reuter’s scale improved from 2.35 thirty days ago to 2.4 now, which indicates a hold consensus from the analyst community. They see QUALCOMM Incorporated (QCOM) price hitting a mean target of $71.03 a share, meaning the stock still has potential that could lift the price another 25.03% Also, the recent close suggests the stock is underpriced by 51.38% compared to the most bullish target.

QUALCOMM Incorporated (QCOM) Returns -11.26% This Year

The company had seen its current volume reaching at 12.22 million shares in the last trade. That compares with the recent volume average of 12.59 million. At the close of regular trading, its last week’s stock price volatility was 2.64% which for the month reaches 2.35%. QUALCOMM Incorporated dipped to as low as $56.77 throughout the day and has returned -11.26% in this year. At one point in the past year, the shares traded as low as $48.92 but has recovered 16.13% since then.

Related Posts:

What Does Insider Trading Tell Us About Cara Therapeutics, Inc. (CARA)?

The most recent non open market insider trade was completed by RHO VENTURES VI LP on 03/17/2016, and was a acquisition of 247,727 shares with a final price of $4.93. The insider now holds 3.07 million shares of Cara Therapeutics, Inc. (CARA). Examining Institutional Ownership at Cara …

Cara Therapeutics, Inc. (NASDAQ:CARA) has seen its stock price gain 0.01, or +0.08%, so far in 2017. In the past 3-month period alone, shares of CARA have appreciated -0.08 – or -0.65%. The stock’s 52-week range is $11.11 to $28.50, and its 3-month range is $11.68 to $16.94.

The average Wall Street analyst rating for Cara Therapeutics, Inc. is Strong Buy, according to the average of 4 analyst scores. Of those analysts, 3 rate stock as a Strong Buy, 1 rate it as Hold, and just no analyst rates it as a Moderate Sell.

Insider Trading Activity for Cara Therapeutics, Inc.

To gain some better insight into how Cara Therapeutics, Inc. (NASDAQ:CARA) is performing, let’s look at some of the company’s recent insider trading activity. Cara Therapeutics, Inc. has had 2 insider trades in the last 3 months, including 0 open market buys and 2 sells. Of those insider trades, 0 shares of Cara Therapeutics, Inc. were purchased and 27,500 shares were sold. The total number of shares traded in the last 90-day period is 27,500.

Insider trading over the last 12 months, however, paints a different picture. In the last year there have been a total of 8 insider trades, including 1 open market buys and 7 sells. Of those transactions, there were 500,000 shares of CARA bought and 324,500 shares sold. The total number of shares traded in the last 12 months is 824,500.



The most recent open market insider trade was Automatic Sell of 12,500 shares on a day where the closing price was 15. The insider, CHALMERS DEREK T, now holds 1.07 million shares of CARA.

The most recent non open market insider trade was completed by RHO VENTURES VI LP on 03/17/2016, and was a acquisition of 247,727 shares with a final price of $4.93. The insider now holds 3.07 million shares of Cara Therapeutics, Inc. (CARA).

Examining Institutional Ownership at Cara Therapeutics, Inc. (NASDAQ:CARA)

According to Cara Therapeutics, Inc.’s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 58.98%. The total amount of shares outstanding is 34.26 million, giving the company a market capitalization of about 458.74 million.

There are 146 institutional holders with active positions, accounting for 19.23 million shares in total. Of those holders, 53 had increased positions amounting to 1.81 million shares, 69 had decreased positions amounting to 2.51 million shares, and 24 holders have a held position accounting for 14.91 million shares.

The top 5 institutional holders, in ascending order, are as follows: STATE STREET CORP with 3.61 million shares, RHO CAPITAL PARTNERS INC with 3.57 million shares, BLACKROCK INC. with 1.76 million shares, VANGUARD GROUP INC with 1.18 million shares, and FMR LLC with 1.16 million shares.

According to Cara Therapeutics, Inc. (CARA) most recent 13F filing, the company has 21 new institutional holders – accounting for 768,893 shares of its common stock. There were 27 sold out positions, amounting to 849,487 shares.


Related Posts:

  • No Related Posts